ReviewCancer metastasis reviews2026
Astrocyte-associated immunosuppressive programs in brain tumors: a STAT3-centered perspective.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astrocytes are increasingly recognized as important contributors to the immunosuppressive tumor microenvironment in glioblastoma and brain metastases. Rather than acting in isolation, tumor-associated astrocytes interact with tumor cells, myeloid populations, and vascular components to shape local immune dysfunction. Here, we propose modular immunosuppressive hubs (MISH) as an astrocyte-centered conceptual framework to describe how distinct suppressive programs may be organized within established tumor niches, with particular emphasis on STAT3-centered signaling. This review systematically deconstructs the composition, spatial regulation, and signaling output of these modules, highlighting how they mediate critical cell-cell communication within the TME. We further emphasize emerging pharmacological strategies aimed at dismantling MISH by targeting these specific signaling pathways, thereby reprogramming TAAs from immunosuppressive barriers into potential allies for immunotherapy. Targeting MISH signaling networks represents a promising avenue to overcome resistance to current immunotherapies and improve outcomes for patients with brain tumors.
Indexed as
Identifiers
42126452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.